论文部分内容阅读
目的:对布地奈德治疗轻-中度溃疡性结肠炎进行循证医学评价。方法:检索外文数据库Pubmed(建库~2014年)、中国期刊全文数据库(CNKI,1994~2014年)、中国科技期刊数据库维普资讯(1989~2014年),搜集布地奈德治疗轻-中度溃疡性结肠炎的所有随机对照试验,由两名评价者进行文献筛选和评价,采用RevMan 5.2软件分析布地奈德治疗轻-中度溃疡性结肠炎的有效性和安全性。结果:筛选和评价后,纳入4篇高质量随机对照试验,分析显示:疗程结束后,口服6 mg或9 mg布地奈德,qd,治疗缓解率与空白组存在显著差异[OR=2.09,95%CI(1.21,3.63)P<0.05];但与2.4 g美沙拉嗪组差异无统计学意义[OR=1.34,95%CI(0.80,2.24),P>0.05];布地奈德组不良反应发生率与对照组差异无统计学意义[OR=0.89,95%CI(0.71,1.11),P>0.05]。结论:口服6 mg或9 mg布地奈德,qd治疗轻-中度溃疡性结肠炎具有一定疗效和安全性,其疗程为4周或8周。
OBJECTIVE: To evaluate the evidence-based medical evaluation of budesonide in the treatment of mild-moderate ulcerative colitis. Methods: The databases of Pubmed (Database - 2014), Chinese Journal Full-text Database (CNKI, 1994-2014) and Chinese Sci-tech Periodical Database (1989-2014) were searched for budesonide to treat mild to moderate ulcer All randomized controlled trials of colitis were screened and evaluated by two reviewers. The efficacy and safety of budesonide in the treatment of mild-to-moderate ulcerative colitis was assessed using RevMan 5.2 software. RESULTS: Four high quality randomized controlled trials were included after screening and evaluation. Analysis showed that oral administration of 6 mg or 9 mg budesonide qd significantly reduced the rate of response to treatment compared with the control group (OR = 2.09, 95 % CI (1.21, 3.63) P <0.05], but no significant difference with 2.4 g mesalazine group [OR = 1.34,95% CI (0.80,2.24, P> 0.05] There was no significant difference between the two groups (OR = 0.89,95% CI (0.71,1.11), P> 0.05]. Conclusions: Administration of budesonide 6 mg or 9 mg orally, qd has some efficacy and safety in the treatment of mild to moderate ulcerative colitis. The course of treatment is 4 weeks or 8 weeks.